Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors


FDA grants expanded approval to wilate as the first VWF concentrate for prophylaxis in all types of von Willebrand disease – Octapharma

Written by | 31 Dec 2023

Octapharma USA announced the expansion of the FDA approval for wilate, von Willebrand Factor/Coagulation Factor VIII Complex (Human) Lyophilized Powder for Solution for Intravenous Injection. The approved label… read more.

Study identifies barriers that limit young men at HIV risk from taking preventative drug

Written by | 4 Dec 2023

Results of a qualitative research study into the uptake of PrEP – a drug which stops HIV infecting the body – suggests that more needs to be done… read more.

EU approves Aquipta for prophylaxis of migraine – AbbVie

Written by | 23 Aug 2023

AbbVie announced that the European Commission has approved Aquipta (atogepant) for the prophylaxis of migraine in adults who have four or more migraine days per month. The approval… read more.

The SAIVE trial for prevention of COVID-19

Written by | 8 Feb 2023

Professor Colleen Aldous is a research professor at in the School of Clinical Medicine at the University of Kwazulu-Natal in South Africa. She recently described the SAIVE trial… read more.

How the totality of evidence for ivermectin informs clinical practice

Written by | 7 Feb 2023

Colleen Aldous, Professor for Medical Research, University of KwaZulu-Natal explains how the evidence supporting the use of ivermectin for covid-19 came together to tell a compelling story. In… read more.

Addressing the totality of evidence for ivermectin

Written by | 6 Feb 2023

When assessing repurposed drugs in a pandemic situation, the totality of evidence should be considered rather than RCTs alone; had this been done the pandemic could have been… read more.

TOGETHER trial shows positive effect for ivermectin

Written by | 5 Feb 2023

The TOGETHER trial was widely reported as showing that ivermectin was not effective in covid-19, but a straightforward analysis of the results reveals a 59 per cent reduction… read more.

Ivermectin – is it safe and effective?

Written by | 4 Feb 2023

The best time to administer ivermectin is at the beginning of a covid-19 infection so that virus is killed and disease progression averted, according to Colleen Aldous, Professor… read more.

What makes the SAIVE study so good?

Written by | 3 Feb 2023

Professor Colleen Aldous is a research professor at the School of Clinical Medicine at the University of Kwazulu-Natal in South Africa. She recently described the SAIVE trial of… read more.

FDA accepts REGEN-COV for priority review for treatment and prophylaxis of COVID-19 – Regeneron Pharma

Written by | 17 Oct 2021

Regeneron Pharmaceuticals, Inc. has announced that the FDA has accepted for priority review a Biologics License Application (BLA) for REGEN-COV (casirivimab and imdevimab) to treat COVID-19 in non-hospitalized… read more.

Ivermectin gathers pace in Europe

Written by | 31 Jan 2021

Article written by Christine Clark. During the past week Slovakia became the first European country to give formal approval for the use of ivermectin for both prophylaxis and… read more.

Ivermectin meta-analysis – the implications

Written by | 27 Jan 2021

Interview and article by Christine Clark Dr Tess Lawrie, Director of the Evidence-based Medicine Consultancy Ltd, describes the implications of her recently-published meta-analysis of ivermectin trials for covid-19…. read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.


You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.